We showed that entrectinib was able to impair ALK-amplified (ALKamp) cells' growth, and proliferation, whereas its activity was less effective in NB cell lines bearing ALK mutation (ALKF1174L, and ALKR1275Q), or wild type (ALKwt) gene. The gene discussed is ALK; the disease is neuroblastoma.